{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:14:13Z","timestamp":1786990453452,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.ijcard.2019.01.037","type":"journal-article","created":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T02:06:57Z","timestamp":1547518017000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective"],"prefix":"10.1016","volume":"285","author":[{"given":"Ella","family":"Zomer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Tonkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Trauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0625-3522","authenticated-orcid":false,"given":"Zanfina","family":"Ademi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2019.01.037_bb0005","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jacc.2013.05.016","article-title":"High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?","volume":"62","author":"Yousuf","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2019.01.037_bb0010","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005610","article-title":"Cumulative exposure to high-sensitivity C-reactive protein predicts the risk of cardiovascular disease","volume":"6","author":"Wang","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2019.01.037_bb0015","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2019.01.037_bb0020","series-title":"ARTG 279239 - Public ARTG Summary Canberra, Australia","author":"Therapeutic Goods Administration","year":"2017"},{"key":"10.1016\/j.ijcard.2019.01.037_bb0025","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/17512433.2016.1204910","article-title":"Canakinumab for the treatment of active systemic juvenile idiopathic arthritis","volume":"9","author":"Orrock","year":"2016","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2019.01.037_bb0030","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2019.01.037_bb0035","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2019.01.037_bb0040","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2019.01.037_bb0045","series-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"key":"10.1016\/j.ijcard.2019.01.037_bb0050","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","article-title":"Modeling good research practices\u2013overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20131","volume":"15","author":"Caro","year":"2012","journal-title":"Value Health J. Int. Soc. Pharmacoeconomics Outcome Res."},{"key":"10.1016\/j.ijcard.2019.01.037_bb0055","doi-asserted-by":"crossref","first-page":"76","DOI":"10.18773\/austprescr.2017.014","article-title":"Economic evaluation of medicines","volume":"40","author":"Taylor","year":"2017","journal-title":"Aust. Prescr."},{"key":"10.1016\/j.ijcard.2019.01.037_bb0060","series-title":"General Record of Incidence of Mortality (GRIM) Books","author":"Australian Institute of Health and Welfare","year":"2017"},{"key":"10.1016\/j.ijcard.2019.01.037_bb0065","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCOUTCOMES.110.957944","article-title":"Population trends of recurrent coronary heart disease event rates remain high","volume":"4","author":"Briffa","year":"2011","journal-title":"Circ. Cardiovasc. Qual. Outcome."},{"key":"10.1016\/j.ijcard.2019.01.037_bb0070","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/CIRCOUTCOMES.111.964700","article-title":"Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010","volume":"5","author":"Smolina","year":"2012","journal-title":"Circ. Cardiovasc. Qual. Outcome."},{"key":"10.1016\/j.ijcard.2019.01.037_bb0075","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1161\/01.STR.0000082382.42061.EE","article-title":"Ten-year survival after first-ever stroke in the perth community stroke study","volume":"34","author":"Hardie","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2019.01.037_bb0080","series-title":"Australian Refined Diagnosis-related Groups (AR-DRG) Data Cubes","author":"Australian Institute of Health and Welfare","year":"2017"},{"key":"10.1016\/j.ijcard.2019.01.037_bb0085","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/1471-2458-12-398","article-title":"Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study","volume":"12","author":"Cobiac","year":"2012","journal-title":"BMC Public Health"},{"key":"10.1016\/j.ijcard.2019.01.037_bb0090","series-title":"The Pharmaceutical Benefits Scheme","author":"Department of Health","year":"2017"},{"key":"10.1016\/j.ijcard.2019.01.037_bb0095","first-page":"93","article-title":"Ilaris (canakinumab) receives a new indication for the treatment of systemic juvenile idiopathic arthritis","volume":"7","author":"Raedler","year":"2013","journal-title":"Am. Health Drug Benefits"},{"key":"10.1016\/j.ijcard.2019.01.037_bb0100","series-title":"Evolocumab for Treatment of High Cholesterol: Effectiveness and Value","author":"Institute for Clinical and Economic Review","year":"2017"},{"key":"10.1016\/j.ijcard.2019.01.037_bb0105","series-title":"The Pharmaceutical Benefits Scheme. Evolocumab","author":"Department of Health","year":"2018"},{"key":"10.1016\/j.ijcard.2019.01.037_bb0110","first-page":"148","article-title":"Adaptation of cost-effectiveness analyses to a single country: the case of bariatric surgery for obesity and overweight","volume":"w14626","author":"Ademi","year":"2018","journal-title":"Swiss Med. Wkly."},{"key":"10.1016\/j.ijcard.2019.01.037_bb0115","author":"Organisation for Economic Co-operation and Development"},{"key":"10.1016\/j.ijcard.2019.01.037_bb0120","author":"Organisation for Economic Co-operation and Development"},{"key":"10.1016\/j.ijcard.2019.01.037_bb0125","series-title":"Health and Welfare Expenditure Series no 58 Cat no HWE 68. Canberra, Australia","article-title":"Health expenditure Australia 2015\u201316","author":"Australian Institute of Health and Welfare","year":"2017"},{"key":"10.1016\/j.ijcard.2019.01.037_bb0130","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jchf.2013.12.003","article-title":"Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction)","volume":"2","author":"Lewis","year":"2014","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.ijcard.2019.01.037_bb0135","series-title":"Guidelines for Preparing a Submission to the Pharmaceutical Benefits Advisory Committee","author":"Department of Health","year":"2016"},{"key":"10.1016\/j.ijcard.2019.01.037_bb0140","series-title":"Australian Public Assessment Report for Canakinumab","author":"Therapeutic Goods Administration","year":"2014"},{"key":"10.1016\/j.ijcard.2019.01.037_bb0145","series-title":"Gouty Arthritis: Canakinumab. Evidence Summary [ESNM23]","author":"National Institute for Health and Care Excellence","year":"2013"},{"key":"10.1016\/j.ijcard.2019.01.037_bb0155","author":"MedicinesComplete"},{"key":"10.1016\/j.ijcard.2019.01.037_bb0160","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","article-title":"Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis","volume":"163","author":"Navarese","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcard.2019.01.037_bb0165","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2019.01.037_bb0170","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jama.2017.9924","article-title":"Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial","volume":"318","author":"Kazi","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2019.01.037_bb0175","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/jamacardio.2017.2762","article-title":"Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease","volume":"2","author":"Fonarow","year":"2017","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ijcard.2019.01.037_bb0180","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/13696998.2017.1284078","article-title":"Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context","volume":"20","author":"Toth","year":"2017","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.ijcard.2019.01.037_bb0185","series-title":"NICE Draft Guidance Recommends New Drugs for Cholesterol Disorder","author":"National Institute for Health and Welfare","year":"2016"},{"key":"10.1016\/j.ijcard.2019.01.037_bb0190","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijcard.2018.04.122","article-title":"The cost-effectiveness of PCSK9 inhibitors - the Australian healthcare perspective","volume":"267","author":"Kumar","year":"2018","journal-title":"Int. J. Cardiol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527318338932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527318338932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T05:23:08Z","timestamp":1554873788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527318338932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":37,"alternative-id":["S0167527318338932"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2019.01.037","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2019.01.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}